Moxifloxacin

Class: Fluoroquinolone

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Binds to type II topoisomerases, gyrase and topoisomerase IV and thus, inhibits DNA cleavage and ligation reactions. It kills bacterial cells by increasing the concentration of enzyme–DNA cleavage complexes, thereby inhibiting cell replication.
Description:	Synthetic quinoline derivative. Oral, intravenous and topical application; off-patent
Year first mentioned:	1989
Highest developmental phase:	Approved by FDA in 2001
Development status:	Approved

Chemical structure(s):
Canonical SMILES:	COC1=C(C(=CC2=C1N(C=C(C2=O)C(=O)O)C3CC3)F)N4C[C@@H]5CCCN[C@@H]5C4
Isomeric SMILES:	COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
InChI:	InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
InChI Key:	FABPRXSRWADJSP-MEDUHNTESA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/152946

External links:
Guide to Pharmacology:	moxifloxacin
Main Source:	https://pubs.acs.org/doi/10.1021/bi5000564
Citations:	https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90866/ https://www.tandfonline.com/doi/abs/10.1517/14740338.2013.796362?journalCode=ieds20